Biotest Aktiengesellschaft (BIO3.DE)
EUR 30.2
(0.67%)
EUR 30.2
(0.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 945.4 Million EUR | 13.64% |
| 2022 | 831.9 Million EUR | 14.94% |
| 2021 | 723.8 Million EUR | 4.94% |
| 2020 | 689.7 Million EUR | 9.22% |
| 2019 | 631.5 Million EUR | 15.43% |
| 2018 | 547.1 Million EUR | -13.26% |
| 2017 | 630.7 Million EUR | 10.24% |
| 2016 | 572.1 Million EUR | 3.94% |
| 2015 | 550.4 Million EUR | -0.36% |
| 2014 | 552.4 Million EUR | 29.73% |
| 2013 | 425.8 Million EUR | 36.08% |
| 2012 | 312.91 Million EUR | -6.9% |
| 2011 | 336.09 Million EUR | 3.5% |
| 2010 | 324.73 Million EUR | -10.69% |
| 2009 | 363.59 Million EUR | 7.36% |
| 2008 | 338.67 Million EUR | 8.92% |
| 2007 | 310.94 Million EUR | 59.71% |
| 2006 | 194.69 Million EUR | -1.73% |
| 2005 | 198.12 Million EUR | -20.85% |
| 2004 | 250.3 Million EUR | 1.47% |
| 2003 | 246.69 Million EUR | -5.55% |
| 2002 | 261.2 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 918.9 Million EUR | -2.8% |
| 2024 Q2 | 839.9 Million EUR | -8.6% |
| 2023 Q4 | 945.4 Million EUR | 6.27% |
| 2023 Q3 | 889.6 Million EUR | 5.83% |
| 2023 Q2 | 840.6 Million EUR | 0.18% |
| 2023 FY | 945.4 Million EUR | 13.64% |
| 2023 Q1 | 839.1 Million EUR | 0.87% |
| 2022 FY | 831.9 Million EUR | 14.94% |
| 2022 Q1 | 734.7 Million EUR | 1.51% |
| 2022 Q2 | 743.2 Million EUR | 1.16% |
| 2022 Q3 | 735.5 Million EUR | -1.04% |
| 2022 Q4 | 831.9 Million EUR | 13.11% |
| 2021 Q1 | 707.1 Million EUR | 2.52% |
| 2021 Q4 | 723.8 Million EUR | 0.08% |
| 2021 Q2 | 723.4 Million EUR | 2.31% |
| 2021 Q3 | 723.2 Million EUR | -0.03% |
| 2021 FY | 723.8 Million EUR | 4.94% |
| 2020 Q2 | 685.9 Million EUR | 6.94% |
| 2020 FY | 689.7 Million EUR | 9.22% |
| 2020 Q1 | 641.4 Million EUR | 1.57% |
| 2020 Q4 | 689.7 Million EUR | 1.73% |
| 2020 Q3 | 678 Million EUR | -1.15% |
| 2019 FY | 631.5 Million EUR | 15.43% |
| 2019 Q3 | 599.3 Million EUR | 6.64% |
| 2019 Q1 | 550.7 Million EUR | 0.66% |
| 2019 Q4 | 631.5 Million EUR | 5.37% |
| 2019 Q2 | 562 Million EUR | 2.05% |
| 2018 FY | 547.1 Million EUR | -13.26% |
| 2018 Q2 | 835.9 Million EUR | 23.45% |
| 2018 Q3 | 542.2 Million EUR | -35.14% |
| 2018 Q1 | 677.1 Million EUR | 7.36% |
| 2018 Q4 | 547.1 Million EUR | 0.9% |
| 2017 Q3 | 622.2 Million EUR | -0.86% |
| 2017 Q4 | 630.7 Million EUR | 1.37% |
| 2017 Q1 | 553.3 Million EUR | -3.29% |
| 2017 Q2 | 627.6 Million EUR | 13.43% |
| 2017 FY | 630.7 Million EUR | 10.24% |
| 2016 FY | 572.1 Million EUR | 3.94% |
| 2016 Q4 | 572.1 Million EUR | 3.01% |
| 2016 Q2 | 565.2 Million EUR | 1.25% |
| 2016 Q3 | 555.4 Million EUR | -1.73% |
| 2016 Q1 | 558.2 Million EUR | 1.42% |
| 2015 FY | 550.4 Million EUR | -0.36% |
| 2015 Q4 | 550.4 Million EUR | -2.52% |
| 2015 Q3 | 564.6 Million EUR | -0.63% |
| 2015 Q2 | 568.2 Million EUR | -0.19% |
| 2015 Q1 | 569.3 Million EUR | 3.06% |
| 2014 Q4 | 552.4 Million EUR | 24.05% |
| 2014 Q3 | 445.3 Million EUR | -0.2% |
| 2014 Q2 | 446.2 Million EUR | 2.15% |
| 2014 Q1 | 436.8 Million EUR | 2.58% |
| 2014 FY | 552.4 Million EUR | 29.73% |
| 2013 Q1 | 285.2 Million EUR | -8.86% |
| 2013 FY | 425.8 Million EUR | 36.08% |
| 2013 Q4 | 425.8 Million EUR | 46.73% |
| 2013 Q3 | 290.2 Million EUR | -0.96% |
| 2013 Q2 | 293 Million EUR | 2.73% |
| 2012 Q4 | 312.91 Million EUR | -0.79% |
| 2012 FY | 312.91 Million EUR | -6.9% |
| 2012 Q1 | 341.4 Million EUR | 1.58% |
| 2012 Q2 | 334.3 Million EUR | -2.08% |
| 2012 Q3 | 315.4 Million EUR | -5.65% |
| 2011 Q4 | 336.09 Million EUR | -12.04% |
| 2011 Q1 | 329.3 Million EUR | 1.41% |
| 2011 Q2 | 372.9 Million EUR | 13.24% |
| 2011 Q3 | 382.1 Million EUR | 2.47% |
| 2011 FY | 336.09 Million EUR | 3.5% |
| 2010 Q4 | 324.73 Million EUR | -4.43% |
| 2010 FY | 324.73 Million EUR | -10.69% |
| 2010 Q3 | 339.8 Million EUR | -2.24% |
| 2010 Q2 | 347.6 Million EUR | 2.48% |
| 2010 Q1 | 339.2 Million EUR | -6.71% |
| 2009 FY | 363.59 Million EUR | 7.36% |
| 2009 Q4 | 363.59 Million EUR | 0.0% |
| 2008 FY | 338.67 Million EUR | 8.92% |
| 2007 FY | 310.94 Million EUR | 59.71% |
| 2006 FY | 194.69 Million EUR | -1.73% |
| 2005 FY | 198.12 Million EUR | -20.85% |
| 2004 FY | 250.3 Million EUR | 1.47% |
| 2003 FY | 246.69 Million EUR | -5.55% |
| 2002 FY | 261.2 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 65.751% |
| CureVac N.V. | 271.53 Million EUR | -248.173% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 0.0% |
| BRAIN Biotech AG | 47.92 Million EUR | -1872.748% |
| Formycon AG | 387.61 Million EUR | -143.904% |
| Heidelberg Pharma AG | 21.01 Million EUR | -4399.069% |
| Medigene AG | 10.65 Million EUR | -8776.995% |